Clinical Trial Overview: Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Study examines whether dapagliflozin is cost-effective when added to standard of care for patients who have heart failure with reduced ejection fraction.

An overview of the clinical trial titled, "Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction."

The study, published in JAMA, estimated the cost-effectiveness of dapagliflozin therapy among patients with chronic heart failure with reduced ejection fraction (HFrEF).

The study indicated that dapagliflozin is cost-effective for patients with HFrEF. As such, the study authors noted that the evidence of clinical benefit and economic value should be considered for increasing therapy rates among patients who have HFrEF with and without diabetes.

Related Videos
Senior Male Research Scientist is Using a Tablet Computer in a Modern High-Tech Laboratory. Genetics and Pharmaceutical Studies and Researches | Image Credit: Gorodenkoff -
Acute psoriasis on the elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis | Image Credit: SNAB -
Portrait of a smiling female pharmacist, male colleague working with drugs in the background. | Image Credit: bnenin -
Dermatologist examining the skin of a patient | Image Credit: thodonal -
Patient with cancer receiving an infusion | Image credit: RFBSIP -
© 2023 MJH Life Sciences

All rights reserved.